Grail teams with Quest on blood test for early cancer detection

By staff writers

February 23, 2021 -- Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood test.

Quest's phlebotomy network will provide blood specimen collection for Galleri once the test becomes available this year in the U.S. The company has approximately 2,200 patient service centers, as well as 5,000 mobile phlebotomists via its ExamOne business.

Grail said it plans to launch Galleri in the second quarter.

Grail to collaborate with top companies for MRD detection
Cancer diagnostics startup Grail has announced collaborations with Amgen, AstraZeneca, and Bristol Myers Squibb to evaluate the ability of Grail's methylation-based...
Holy Grail: Ilumina nabs cancer testing firm in $8B deal
Illumina has agreed to acquire cancer diagnostics startup Grail for $8 billion in cash and stock. Grail utilizes Illumina's next-generation sequencing...
Grail raises $390M for multicancer liquid biopsy
Menlo Park, CA-based startup Grail has raised an additional $390 million to advance its multicancer blood test, which is being validated for the...
Grail kicks off real-world study of multicancer blood test
Grail announced that a prospective interventional study is underway to evaluate its multicancer blood test for guiding patient management.
How Grail's blood test stacks up in gastrointestinal cancers
An investigational blood test developed by startup Grail has high sensitivity and specificity across a range of gastrointestinal cancer types, though...

Copyright © 2021

Last Updated bc 2/23/2021 9:30:36 PM